Exponent-backed BBI Group, an independent provider of immuno-diagnostic reagents and contract services, completed the acquisition of DIARECT, a supplier of autoimmune antigen products. Financial terms were not disclosed. "The acquisition of DIARECT immediately enhances our portfolio and positions BBI as a ‘complete’ immunoassay reagent supplier and therefore a natural partner for our customers. The combined capability enables BBI to further service high growth disease segments such as cancer, cardiac conditions and diabetes, while also enabling BBI to drive geographic expansion for DIARECT, which will benefit from a bigger sales force," Mario Gualano, BBI Group CEO.